MedPath

Effect Of Abhaya VatakaIn The Management OfFatty Liver Disease.

Phase 1
Conditions
Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
Registration Number
CTRI/2024/07/069931
Lead Sponsor
I
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Subjects, diagnosed with NAFLD according to the USG report, standard criteria accepted by the American Gastroenterology Association.

Subjects diagnosed with Grade I & II Non Alcoholic Fatty liver Disease Subjects between the age of 18 and 60 years

Subjects irrespective of gender and socio-economic status.

Subjects who are willing to sign the consent form and agreeing to follow the

protocol of the study.

Exclusion Criteria

1) Subjects with history of alcohol intake more than 20 g/ day for women and more than 30g/day for men

2) Diagnosed case of renal, respiratory, cardiovascular (including IHD), neurologic diseases, Hepatocellular carcinoma, and liver cirrhosis.

3) Subjects with history of following drug intake -steroids, synthetic estrogens, heparin, and amiodarone, valproic acid, antiviral agents.

4) Pregnant women, lactating mothers and mentally challenged persons.

5) Uncontrolled Diabetes Mellitus and Hypertension.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath